行情

IMUC

IMUC

IMMUNOCELLULAR
OTCPK

实时行情|Nasdaq Last Sale

0.300
+0.070
+30.43%
已收盘, 15:59 05/19 EDT
开盘
0.300
昨收
0.230
最高
0.300
最低
0.300
成交量
969
成交额
291
52周最高
0.750
52周最低
0.140
市值
125.80万
市盈率(TTM)
-0.0631
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解IMUC最新的财务预测,通过IMUC每股收益,每股净资产,每股现金流等数据分析IMMUNOCELLULAR近期的经营情况,然后做出明智的投资选择。
EPS
实际EPS
预期EPS
-9.13-6.85-4.56-2.28
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
机构持股
总机构数: 1
机构持股: 95
持股比例: 0.00%
总股本: 419.35万
类型机构数股数
增持
0
0
建仓
0
0
减持
0
0
平仓
3
27.66万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.00%
制药与医学研究
+0.51%
高管信息
Lead Director
Rahul Singhvi
Director
John Yu
Independent Director
Gregg Lapointe
Independent Director
Mark Schlossberg
Independent Director
Gary Titus
暂无数据
暂无数据
IMUC 简况
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

微牛提供ImmunoCellular Therapeutics Ltd(OTCPK-IMUC)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMUC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMUC股票基本功能。